Key Highlights:
- CVS Health Corp (CVS, Financial) is undergoing vital strategic changes, focusing on healthcare provider services.
- Despite challenges in retail sectors, analysts predict a potential upside of over 13% for CVS stock.
- GuruFocus metrics suggest CVS is undervalued, with a projected 27.25% increase in fair value.
CVS Health (CVS) is navigating a challenging landscape with mixed performance across its divisions. While its retail pharmacies struggle, the company aims to become a leading healthcare provider. CEO David Joyner is focused on strategic realignments, including exiting the ACA marketplace due to unprofitability.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for CVS Health Corp (CVS, Financial) is $76.38, with a high estimate reaching $90.00 and a low of $67.00. This average target suggests a potential upside of 13.23% from the current price of $67.46. Investors seeking more detailed estimate data can find it on the CVS Health Corp (CVS) Forecast page.
Analyst Ratings and Recommendations
The consensus among 29 brokerage firms gives CVS Health Corp (CVS, Financial) an average recommendation of 2.2, indicating an "Outperform" status. This rating is part of a scale ranging from 1 to 5, where 1 signifies a Strong Buy and 5 denotes Sell.
GuruFocus Valuation Insights
According to GuruFocus estimates, the projected GF Value for CVS Health Corp (CVS, Financial) in one year is $85.84, indicating a substantial upside of 27.25% from its current price of $67.46. The GF Value is a calculated estimate of the stock's fair trading value, based on historical trading multiples, past business growth, and future performance estimates. For further data, visit the CVS Health Corp (CVS) Summary page.
